Jade Biosciences Inc. Common Stock (JBIO)
Stock · NASDAQ · Health Care
$13.48as of 10/16/2026
Price chart
Active signals
JBIO Signal Track Record
How signals performed across all stocks →What JBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 27 | +2.4% | 59% | August 12, 2026 |
| Bollinger Band Breakdown | 18 | +3.9% | 56% | September 16, 2026 |
| Volume Spike | 17 | +12.6% | 59% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -8.6% | 40% | September 14, 2026 |
| Any 20-session window (baseline) | +0.4% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc.…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 55
- Website
- jadebiosciences.com/
Fundamentals
- 1-day range
- $13.45$14.18
- Market cap
- $1.10B
- P/E (trailing)
- —
- P/E (forward)
- -5.17
- EPS (trailing)
- $-2.84
- Dividend yield
- —
- Beta
- 1.78
- Avg. volume
- 891.7K
- Dividend pay date
- April 28, 2025
Forecasts
8 analyst ratings
Jade Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price TargetBenzinga · 10/1/2026
- HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price TargetBenzinga · 10/1/2026
- Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - SlideshowSeekingAlpha · 9/30/2026
- Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis TranscriptSeekingAlpha · 9/30/2026
- Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026Yahoo · 9/30/2026
Insider Activity
Insider Actions →- Mark Eisner · June 25, 2026 · Grant47.7K
- CAIN CHRISTOPHER W. · June 9, 2026 · Grant34.8K
- Lawrence Otto Klein · June 9, 2026 · Grant34.8K
- Lavelle Erin · June 9, 2026 · Grant34.8K
- Harwin Peter Evan · June 9, 2026 · Grant34.8K
- Eric Dobmeier · June 9, 2026 · Grant34.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 49.44M
- Total value held
- $693.69M
- Institutional holders
- 117
- Unknown7.09M
- Unknown4.55M
- Unknown3.67M
- Unknown3.50M
- Unknown3.22M
- Unknown3.11M
- Unknown2.31M
- Unknown1.80M
- Unknown1.64M
- Unknown1.58M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Jade Biosciences Schedules Conference Participation
Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.
Jade Biosciences Schedules Conference Participation. Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.